urothelial cancer
Showing NaN - NaN of 7
Urothelial Cancer Trial in Worldwide (Nivolumab, Ipilimumab, Gemcitabine)
Recruiting
- Urothelial Cancer
- Nivolumab
- +4 more
-
Birmingham, Alabama
- +196 more
Jan 17, 2023
Advanced Malignancies, NSCLC, Ovarian Cancer Trial in Worldwide (Avelumab, Lorlatanib, Talazoparib)
Recruiting
- Advanced Malignancies
- +4 more
- Avelumab
- +7 more
-
Fayetteville, Arkansas
- +61 more
Jan 10, 2023
Urothelial Cancer Trial in Worldwide (MEDI4736 (Durvalumab), Tremelimumab, Cisplatin)
Active, not recruiting
- Urothelial Cancer
- MEDI4736 (Durvalumab)
- +4 more
-
Los Angeles, California
- +221 more
Nov 2, 2022
Urothelial Cancer Trial in Worldwide (Avelumab, Best Supportive Care, Following the planned interim analysis for this study:
Active, not recruiting
- Urothelial Cancer
- Avelumab
- +2 more
-
Aurora, Colorado
- +370 more
Oct 24, 2022